Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals announced its participation in the 2025 International Society for Autism Research Annual Meeting, where it will present findings on genetic testing for autism spectrum disorders. This presentation highlights the shortcomings in current genetic testing methodologies, aiming to improve diagnosis for children with developmental delays. Participation in this conference emphasizes Neuren’s commitment to advancing research in autism and its broader focus on neurological disorders, potentially impacting stakeholders by enhancing the company’s industry positioning and fostering further advancements in genetic testing.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is a company focused on developing new drug therapies for serious neurological disorders that emerge in early childhood and have limited treatment options. The company has been granted orphan drug designation in the United States, which encourages the development of therapies for rare diseases. Neuren’s DAYBUE™ (trofinetide) is approved for the treatment of Rett syndrome and is licensed to Acadia Pharmaceuticals for further development. The company’s second drug candidate, NNZ-2591, is in development for various neurodevelopmental disorders and has shown positive results in Phase 2 trials.
YTD Price Performance: 7.22%
Average Trading Volume: 1,200
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.07B
See more insights into NEU stock on TipRanks’ Stock Analysis page.
